C-MYC copy-number gain is an independent prognostic factor in patients with colorectal cancer

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Lee, Kyu Sang ^a   Kwak, Yoonjin ^b   Nam, Kyung Han ^c   Kim, Duck Woo ^a   Kang, Sung Bum ^a   Choe, Gheeyoung ^a,b   Kim, Woo Ho ^b   Lee, Hye Seung ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MYC PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DISTANT METASTASIS; EXON; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC GAIN; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOGENE C MYC; ONCOGENE K RAS; PERINEURAL INVASION; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; CANCER GRADING; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; TUMOR INVASION;

AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES;

EID: 84947253734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139727     Document Type: Article

References (35)

1. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999; 18(19):3004-16. Epub 1999/06/23. doi: 10.1038/sj.onc.1202746 PMID: 10378696.
2. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. Epub 2010/02/19. doi: 10.1038/nature08822 PMID: 20164920; PubMed Central PMCID: PMCPmc2826709.
3. Secombe J, Pierce SB, Eisenman RN. Myc: a weapon of mass destruction. Cell. 2004; 117(2):153-6. Epub 2004/04/16. PMID: 15084254.
4. Singh AM, Dalton S. The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell stem cell. 2009; 5(2):141-9. Epub 2009/08/12. doi: 10.1016/j.stem.2009.07.003 PMID: 19664987; PubMed Central PMCID: PMCPmc2909475.
5. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell cycle. 2008; 7(5):592-6. PMID: 18256542.
6. Luscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene. 2012; 494 (2):145-60. Epub 2012/01/10. doi: 10.1016/j.gene.2011.12.027 PMID: 22227497.
7. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Seminars in cancer biology. 2006; 16(4):318-30. Epub 2006/08/29. doi: 10.1016/j.semcancer.2006.07.015 PMID: 16934487.
8. Rochlitz CF, Herrmann R, de Kant E. Overexpression and amplification of c-myc during progression of human colorectal cancer. Oncology. 1996; 53(6):448-54. Epub 1996/11/01. PMID: 8960139.
9. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487 (7407):330-7. Epub 2012/07/20. doi: 10.1038/nature11252 PMID: 22810696; PubMed Central PMCID: PMCPmc3401966.
10. Toon CW, Chou A, Clarkson A, DeSilva K, Houang M, Chan JC, et al. Immunohistochemistry for myc predicts survival in colorectal cancer. PLoS One. 2014; 9(2):e87456. doi: 10.1371/journal.pone. 0087456 PMID: 24503701; PubMed Central PMCID: PMC3913591.
11. Knijn N, Tol J, Punt CJ. Current issues in the targeted therapy of advanced colorectal cancer. Discovery medicine. 2010; 9(47):328-36. PMID: 20423677.
12. Van Cutsem E. Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer. Clin Colorectal Cancer. 2007; 6 Suppl 2:S60-5. PMID: 18021489.
13. Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004; 325(3):784-91. doi: 10.1016/j.bbrc.2004. 10.111 PMID: 15541358.
14. Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol. 2011; 68(4):1045-55. doi: 10.1007/s00280-011-1586-z PMID: 21340604.
15. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010; 16(3):790-9. doi: 10.1158/1078-0432.CCR-09-2446 PMID: 20103678.
16. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park do J, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(14):4154-63. Epub 2007/07/20. doi: 10.1158/1078-0432.ccr-07-0173 PMID: 17634543.
17. Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP, et al. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecologic oncology. 2009; 114(3):472-9. doi: 10.1016/j.ygyno.2009.05.012 PMID: 19524285.
18. Kim JH, Bae JM, Kim KJ, Rhee YY, Kim Y, Cho NY, et al. Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status. Korean J Pathol. 2014; 48 (4):276-82. doi: 10.4132/KoreanJPathol.2014.48.4.276 PMID: 25214859; PubMed Central PMCID: PMC4160590.
19. Lee S, Brophy VH, Cao J, Velez M, Hoeppner C, Soviero S, et al. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch. 2012; 460(2):141-9. doi: 10.1007/s00428-011-1180-0 PMID: 22173329; PubMed Central PMCID: PMC3303066.
20. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984 PMID: 24101045.
21. Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D. Correlations between c-myc gene copynumber and clinicopathological parameters of ovarian tumours. Eur J Cancer. 2006; 42(5):674-9. doi: 10.1016/j.ejca.2005.11.022 PMID: 16458500.
22. C D. Statistics without maths for psychology: using SPSS for windows. J R, editor. London: Prentice Hall; 2004.
23. Choi JS, Seo J, Jung EJ, Kim EJ, Lee GK, Kim WH. c-MYC amplification in mucinous gastric carcinoma: a possible genetic alteration leading to deeply invasive tumors. Anticancer research. 2012; 32 (11):5031-7. Epub 2012/11/17. PMID: 23155275.
24. Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, et al. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Human pathology. 2013; 44(8):1617-23. Epub 2013/04/12. doi: 10.1016/j. humpath.2013.01.012 PMID: 23574779.
25. Seo AN, Yang JM, Kim H, Jheon S, Kim K, Lee CT, et al. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 2014; 110(11):2688-99. doi: 10.1038/bjc.2014.218 PMID: 24809777; PubMed Central PMCID: PMC4037828.
26. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. Journal of clinical pathology. 2007; 60(7):768-72. Epub 2006/08/03. doi: 10.1136/jcp.2006.038281 PMID: 16882699; PubMed Central PMCID: PMCPmc1995777.
27. Smith DR, Goh HS. Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res. 1996; 2(6):1049-53. PMID: 9816266.
28. Erisman MD, Litwin S, Keidan RD, Comis RL, Astrin SM. Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival. Cancer research. 1988; 48(5):1350-5. Epub 1988/03/01. PMID: 3342413.
29. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151(1):56-67. Epub 2012/10/02. doi: 10.1016/j.cell.2012. 08.026 PMID: 23021215; PubMed Central PMCID: PMCPmc3462372.
30. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3 PMID: 20619739.
31. Gnanasampanthan G, Elsaleh H, McCaul K, Iacopetta B. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. J Pathol. 2001; 195(5):543-8. doi: 10.1002/path.990 PMID: 11745689.
32. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304(16):1812-20. doi: 10.1001/jama.2010.1535 PMID: 20978259.
33. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer. 2013; 108(8):1757-64. doi: 10.1038/bjc.2013.118 PMID: 23511557; PubMed Central PMCID: PMC3668469.
34. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005; 6(5):279-86. doi: 10.1016/S1470-2045(05) 70102-9 PMID: 15863375.
35. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26(3):374-9. doi: 10.1200/JCO.2007.12.5906 PMID: 18202412.